Company presentation 2017 vs. 2

Biem Pharmaceuticals is

Pharmaceutical manufacturer with headquarters in Ankara Pharmaceutical marketing and distribution company Proprietary portfolio of high-value branded pharmaceutical products in Turkey Global presence advancing in more than 23 countries Committed to innovative solutions in Oncology, Hematology, Radiology, Ophthalmology, Neurology. To become the FIRST REMEDY for saving To achieve growth in our therapeutic field lives by increasing life quality with high with an innovative approach and steady tech, pioneering products and ONLY growth REMEDY able to provide drugs always focused to produce the best quality produced with innovative technology products, safe and efficient, by searching without pursuing high profit margins, for innovative solutions for happy and healthy illnesses that affects only a small lifes percentage of the population

To increase the quality of our health services in all its activities, while preserving the ethical values of the health industry Biem as part of its strategy has accelerated its expansion activities and products portfolio with a big focus on registration sales, marketing and manufacturing on the domestic and international pharmaceutical market. Biem Function &Value Chain

Distributor Supply Management & Chain/ Commercial CS

Accounting Regional Representation Manufacturi Planning / Forecast & Biem ng through Demand CMOs

Local Distribution, Regional Sales and Marketing Technical Regulatory Distributor

Direct Local Distribution

R&D Strong R&D team

Regulatory, Technical & Consultancy Strong Regulatory Team, Market Assessment, Business Development Biem has key partnerships with leading Global Pharmaceutical companies: Active Sales

Canada Azerbaijan Romania Russia Belarus Kuwait Chile Georgia Yemen Bosnia&H Kyrgzystan Albania Sri Lanka Moldova Vietnam India Sudan Costa Rica Tunisia Panama Myanmar Irak Makedonya Malaeysia Pakistan Yemen Domestic Market: International Market: Malaysia a steady growth in the therapeutic market is International business is increasing due to our expected due to our ongoing portfolio. overseas sales activity through product registration in more than 23 countries. Biem portfolio consists of 31 human products, of which:

Others Radiocontrast %12 Imaging 12%

Oncology 19.4% Opthalmology 30 %

Transplantology 6%

Intensive Care %12 Anti-Infectives %9

Key moments Others : 2012: launch of the Emaray and Pamiray Nephrology/Dialysis Nervous System 2014: launch of the Oncology and Ophthalmology Portfolio Anesthesia 2015: launch of the Intensive Care Portfolio Drug Name Active ingredient Treatment Area Launch date

PAMIRAY® 300/370 Iopamidol CT Diagnostic imaging agent 50,100 ml 2012

BIEMEXOL® 300/350 50,100,200ml vials Iohexol CT Diagnostic imaging agent 2015

EMARAY® Gadopentetate Magnetic Resonance imaging 10,15,20 ml 2012 dimeglumine (MRI)

GADODIEM ® Magnetic Resonance imaging 287 mg/ml in 10,15,20 ml Gadodiamide (MRI) 2015 CTI & MRI Market Potential

Total Market Units Year Euro

MRI 1,182,949.00 vials 22,789,012.00 Euro

CTI 2,822,135.00 vials 31,444,105.00 Euro Units MAT/8/2017 IMS TENDER MARKET Rate (%) units 1.22 % 10.65 % T0 DIAGNOSTIC AGENTS 1,541,240 14,122,766.2 $ 53.77 % IOHEXOL 525,950 33.4 % OMNIPAQUE (Opakim) 525,950 33.4 % IOPROMIDE 506,176 32.1 % ULTRAVIST (Bayer) 506,176 32.1 % IOHEXOL 182,838 11.6 % BIEMEXOL (Biem) 182,838 32.06 % IOVERSOL 168,086 10.7 % OPTIRAY (Mallinckrodt) 168,086 10.7 % IOHEXOL 140.034 8.9 % KOPAQ (Onko) 140.034 IODIXANOL 18,213 1.2 % VISIPAQUE (Opakim) 18,213 1.2 % Iopamidol 10,516 1. IOHEXOL 2. IOPROMIDE 0.7 % PAMIRAY (BIEM) 10,526 3. IOVERSOL 4. IOPAMIDOL IOBITRIDOL 9,721 0.6 % 5. IODIXANOL 6. IOBITRIDOL XENETIX (Guerbet) 9,721 0.6 % 7. IOMEPROL IOMEPROL 8,692 0.6 % IOMERON (Santa Farma) 8,692 0.6 % IOPAMIDOL 2,653 0.2 % IOPAMIRO (Santa Farma 2,653 0.2 % Units TENDER MARKET MAT/8/2017 IMS Rate (%) 5.1 % 25.4 % Units 6.5 % T01E0 MRI AGENTS 452,441 6,758,845.15 $ GADOTERIC ACID 165,405 36,60% DOTAREM GUERBET 165,405 36,60% GADOPENTETIC ACID 85,406 18,90% MAGNEVIST BAYER 85,406 18,90% 11.5 % GADOBUTROL 71,803 15.90 % GADOVIST BAYER 71,803 15.90 % EMARAY 55,657 12,30% BIEM ILAC 55,657 12,30% GADODIAMIDE 26,122 5.80 % OMNISCAN OPAKIM 26,122 5.80 % GADOVERSETAMIDE 20,543 4,50% OPTIMARKCOVIDIEN 20,543 4,50% 13.8 % 1. GADOTERIC ACID GADOBENIC ACID 11,522 2,60% MULTIHANCE SANTA 2. GADOPENTETETIC ACID FARMA 11,522 2,60% 3. GADOBUTROL GADODIAMIDE 7,901 1,70% 4. GADODIAMIDE BIEM GADODIEM 7,901 1,70% 5. GADOVERSETAMIDE GADOXETIC ACID 7,204 1.6 % 6. GADOBENIC ACID PRIMOVIST BAYER 7,204 1.6 % 7. GADOXETIC ACID GADODIAMIDE 888 0.2 % Gadotu (Onko) 888 0.2 % Drug Name Active ingredient Treatment Area Launch date BUSLERA® Antineoplastic Agent / 6 mg / mL Busulfan conditioning treatment prior to 2014 conventional (HPCT) BEASTIN® Antineoplastics, Alkylating agent/Chronic Lymphocytic 25 mg, 100 mg Bendamustine HCl 2014 Leukemia, Non-Hodgkin Lymphoma

OCLADRA ® Antineoplastics, Antimetabolite 10 mg / 5 mL Cladribine / Hairy Cell Leukemia 2014

VOTRON® Anti-vomiting and anti- 250 mcg / mL nausea/Chemotherapy side Palonosetron effects 2012 Busulfan Market Potential

Total Market Units Year Euro

Busulfan 12,294 Vials 812,048.00 Euro 3 %

Units TENDER MARKET YTD/12/2016 Rate (%) (Absolute)

BUSULFAN 12,294 52 % 45 % BUSLERA 6532 %52 6532 BIEM ILAC 6532 VIAL INF 60 MG 1 10 MG BUSILVEX 5498 %45 5498 IBRAHIM AMP INFUSION 6 MG 1 10 5498 ML MYLERAN 264 %3 1. Busilvex 2. Buslera 3. Myleran VLD DANISMANLIK 264 TABS 2 MG 100 264 Drug Name Active ingredient Treatment Area Launch date BIEMIB® Mantle cell Lymphoma, Non- 3.5 mg Bortezomib Hodgkin Lymphomai Multiple 2015 Myeloma

LETROKS® Antineoplastic agent/Breast 2 mg, 5 mg Letrozol cancer 2009 Drug Name Active ingredient Treatment Area Launch date

CALSIPAR ® Systemic Hormonal Preparations – Anti- 10 mcg / 2 Ml 5 mvg / mL Paricalcitol Parathyroid Agents / Its primary use in 2017 medicine is in the treatment

EMFER® 100mg/5 ml ampoules Iron Sucrose Haematinics (iron supplements) 2014

BIEMPARIN® Heparine sodium Anticoagulant therapy 2016 4mg/4ml

BIEMEFRIN® Norepinephrine Antihypotensives/Acute hypotension 2014 4mg/4ml

ERBINNA® Omeprazole Sodium Proton Pump Inhibitors / Gastroesophageal 2017 40 mg Reflux Disease, Peptic Ulcer Disease and Zollinger-Ellison Syndrome. Drug Name Active ingredient Treatment Area Launch date MRSACIN® Tygecycline Antibiotic/Antibacterial for 2014 50mg systemic use

TROZASIN ® Voriconazole Antifungal, Systemic/Invasive 2016 200 mg/ aspergillosis; Nonneutropenic candidemia;

KOLISTATE® Colistimethate Sodium Anti-Infectives-Other 2017 150 mg Antibacterials / Selected Aerobic Gram-Negative Pathogens in Patients with Limited Treatment Options Drug Name Active ingredient Treatment Area Launch date SEDOZOLAM® Midazolam Anesthetic/Hypnotics/Sedativ 2017 5mg/5ml, 15mg/3ml e/Preoperative Sedation;

LOKARIL® Lidocaine / Prilocaine Local Anesthetics / Dermal 2017 %5 Cream Anesthesia, Intravenous Catheter Insertion, Blood Sampling, Superficial Surgical Procedures and Topical Anaesthesia of Leg Ulcers for Cleansing or Debridement Drug Name Active ingredient Treatment Area Launch date

PARGICYL ® 50 mg / 5 mL Nerbous System – Dopamine Apomorphine HCl Agonists / Parkinson’s Disease 2017 20 mg / 2 mL Drug Name Active ingredient Treatment Area Launch date

ZARIDINEX ® Anti-infective quinolone 0,3% Ophthalmic antibiotics/bacterial eye Ofloxacine 2014 solution infection

ENFLUAT® Nonsteroidal anti-inflammatory 0,4% Ophthalmic Ketorolac 2014 drug for ophthalmic use solution Tromethamine Future of BIEM

Stage 1 R&D Center

Stage 2 New Manufacturing Oncology Facility Thank you

Address:Turgut Reis Cad. No:21 Tandoğan/Ankara Phone: (0312) 230 29 29 Fax: (0312) 230 68 00